Estrogen receptor prevents p53-dependent apoptosis in breast cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 44, 2012, Pages 18060-18065

  Bailey, Shannon T ^a,b   Shin, Hyunjin ^a,c   Westerling, Thomas ^a,b   Liu, Xiaole Shirley ^a,c   Brown, Myles ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cistrome; DNA damage; Doxorubicin; Nuclear receptor; Nutlin

Indexed keywords

DOXORUBICIN; ESTRADIOL; ESTROGEN RECEPTOR; FULVESTRANT; PROTEIN P53; TAMOXIFEN;

APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; GENE TARGETING; GENETIC TRANSCRIPTION; GENOME; HORMONE ACTION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN FUNCTION;

APOPTOSIS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84868129083     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1018858109     Document Type: Article

References (57)

1. Kanavos P (2006) The rising burden of cancer in the developing world. Ann Oncol 17 (Suppl 8):viii15-viii23.
2. Soørlie T, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874.
3. Sorlie T, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100(14):8418-8423.
4. Osborne CK, Zhao H, Fuqua SA (2000) Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol 18(17):3172-3186.
5. Osborne CK, Schiff R (2005) Estrogen-receptor biology: Continuing progress and therapeutic implications. J Clin Oncol 23(8):1616-1622.
6. Ali S, Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2(2):101-112.
7. Wakeling AE, Dukes M, Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51(15):3867-3873.
8. Dauvois S, White R, Parker MG (1993) The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 106(Pt 4):1377-1388.
9. Wijayaratne AL, McDonnell DP (2001) The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J Biol Chem 276(38):35684-35692.
10. Marsaud V, Gougelet A, Maillard S, Renoir JM (2003) Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasomemediated stability, and transcriptional activity in human breast cancer cells. Mol Endocrinol 17(10):2013-2027.
11. Konduri SD, et al. (2010) Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci USA 107(34):15081-15086.
12. Vousden KH (2000) p53: Death star. Cell 103(5):691-694.
13. Prives C, Hall PA (1999) The p53 pathway. J Pathol 187(1):112-126.
14. Turpin E, et al. (2002) Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 21(49):7593-7597.
15. Sayeed A, et al. (2007) Estrogen receptor alpha inhibits p53-mediated transcriptional repression: Implications for the regulation of apoptosis. Cancer Res 67(16):7746-7755.
16. Vassilev LT, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303(5659):844-848.
17. Carroll JS, et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat Genet 38(11):1289-1297.
18. Rhodes DR, et al. (2007) Molecular concepts analysis links tumors, pathways, mechanisms, and drugs. Neoplasia 9(5):443-454.
19. Lupien M, et al. (2008) FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132(6):958-970.
20. Sbisà E, et al. (2007) p53FamTaG: A database resource of human p53, p63 and p73 direct target genes combining in silico prediction and microarray data. BMC Bioinformatics 8(Suppl 1):S20.
21. Liang G, Wolfgang CD, Chen BP, Chen TH, Hai T (1996) ATF3 gene. Genomic organization, promoter, and regulation. J Biol Chem 271(3):1695-1701.
22. Nilsson M, Ford J, Bohm S, Toftgard R (1997) Characterization of a nuclear factor that binds juxtaposed with ATF3/Jun on a composite response element specifically mediating induced transcription in response to an epidermal growth factor/Ras/Raf signaling pathway. Cell Growth Differ 8(8):913-920.
23. Hsu JC, Bravo R, Taub R (1992) Interactions among LRF-1, JunB, c-Jun, and c-Fos define a regulatory program in the G1 phase of liver regeneration. Mol Cell Biol 12(10): 4654-4665.
24. Rouault JP, et al. (1996) Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. Nat Genet 14(4):482-486.
25. Kawakubo H, et al. (2006) Loss of B-cell translocation gene-2 in estrogen receptorpositive breast carcinoma is associated with tumor grade and overexpression of cyclin d1 protein. Cancer Res 66(14):7075-7082.
26. Möllerström E, et al. (2010) Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray. BMC Cancer 10:296.
27. Cortes U, et al. (2000) BTG gene expression in the p53-dependent and -independent cellular response to DNA damage. Mol Carcinog 27(2):57-64.
28. Matsuda S, Rouault J, Magaud J, Berthet C (2001) In search of a function for the TIS21/PC3/BTG1/TOB family. FEBS Lett 497(2-3):67-72.
29. Régnier CH, et al. (1995) Presence of a new conserved domain in CART1, a novel member of the tumor necrosis factor receptor-associated protein family, which is expressed in breast carcinoma. J Biol Chem 270(43):25715-25721.
30. Sax JK, El-Deiry WS (2003) Identification and characterization of the cytoplasmic protein TRAF4 as a p53-regulated proapoptotic gene. J Biol Chem 278(38):36435-36444.
31. Liu G, Schwartz JA, Brooks SC (2000) Estrogen receptor protects p53 from deactivation by human double minute-2. Cancer Res 60(7):1810-1814.
32. Gyorffy B, et al. (2010) An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 123(3):725-731.
33. Kansra S, Yamagata S, Sneade L, Foster L, Ben-Jonathan N (2005) Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol 239(1-2):27-36.
34. Somaï S, et al. (2003) Antiestrogens are pro-apoptotic in normal human breast epithelial cells. Int J Cancer 105(5):607-612.
35. Hur J, et al. (2006) Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein. Cancer Res 66(20):10153-10161.
36. Yan C, Lu D, Hai T, Boyd DD (2005) Activating transcription factor 3, a stress sensor, activates p53 by blocking its ubiquitination. EMBO J 24(13):2425-2435.
37. Karmakar S, Foster EA, Smith CL (2009) Estradiol downregulation of the tumor suppressor gene BTG2 requires estrogen receptor-alpha and the REA corepressor. Int J Cancer 124(8):1841-1851.
38. Takahashi F, et al. (2011) Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib. Oncogene 30 (27):3084-3095.
39. Bièche I, et al. (1996) Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer Res 56(17):3886-3890.
40. Tomasetto C, et al. (1995) Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics 28(3):367-376.
41. Yu CL, et al. (1997) The tumor suppressor p53 is a negative regulator of estrogen receptor signaling pathways. Biochem Biophys Res Commun 239(2):617-620.
42. Welboren WJ, et al. (2009) ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J 28(10):1418-1428.
43. Ross-Innes CS, et al. (2010) Cooperative interaction between retinoic acid receptoralpha and estrogen receptor in breast cancer. Genes Dev 24(2):171-182.
44. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS (2011) FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet 43(1):27-33.
45. Carroll JS, et al. (2005) Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122(1):33-43.
46. Huang da W, et al. (2007) DAVID Bioinformatics Resources: Expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 35(Web Server issue):W169-W175.
47. Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44-57.
48. Liu T, et al. (2011) Cistrome: An integrative platform for transcriptional regulation studies. Genome Biol 12(8):R83.
49. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T (2011) Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics 27(3):431-432.
50. van de Vijver MJ, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999-2009.
51. Kao KJ, Chang KM, Hsu HC, Huang AT (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: Implications for treatment optimization. BMC Cancer 11:143.
52. Loi S, et al. (2007) Definition of clinically distinct molecular subtypes in estrogen receptor- positive breast carcinomas through genomic grade. J Clin Oncol 25(10): 1239-1246.
53. Loi S, et al. (2008) Predicting prognosis using molecular profiling in estrogen receptorpositive breast cancer treated with tamoxifen. BMC Genomics 9:239.
54. Wang Y, et al. (2005) Gene-expression profiles to predict distant metastasis of lymphnode- negative primary breast cancer. Lancet 365(9460):671-679.
55. Hatzis C, et al. (2011) A genomic predictor of response and survival following taxaneanthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-1881.
56. Sotiriou C, et al. (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100(18): 10393-10398.
57. Desmedt C, et al. (2007) Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 13(11):3207-3214.